CANCER CHEMOTHERAPY AND PHARMACOLOGY
Scope & Guideline
Empowering researchers with high-impact studies in chemotherapy.
Introduction
Aims and Scopes
- Chemotherapy and Pharmacology:
The journal primarily focuses on the pharmacological aspects of cancer treatment, including the efficacy and safety of chemotherapeutic agents, drug-drug interactions, and the development of novel therapeutic agents. - Pharmacokinetics and Drug Metabolism:
A consistent emphasis on studying the pharmacokinetics of various chemotherapeutic agents and their metabolites, including factors influencing drug absorption, distribution, metabolism, and excretion in different patient populations. - Pharmacogenomics and Personalized Medicine:
Research articles often explore the impact of genetic polymorphisms on drug metabolism and therapeutic outcomes, aiming to personalize chemotherapy regimens based on individual genetic profiles. - Combination Therapies and Treatment Optimization:
The journal highlights studies on combination therapies, including the evaluation of synergistic effects between chemotherapy agents and targeted therapies, as well as optimization of dosing regimens to enhance patient outcomes. - Mechanisms of Drug Resistance:
Significant attention is given to understanding the mechanisms underlying drug resistance in various cancer types, with studies aimed at identifying potential biomarkers and therapeutic targets.
Trending and Emerging
- Targeted and Immunotherapy:
An increasing number of studies focus on targeted therapies and immunotherapies, reflecting a significant trend towards understanding and enhancing the efficacy of these innovative treatment modalities in various cancers. - Biomarkers and Precision Medicine:
There is a growing emphasis on identifying biomarkers for predicting treatment response and toxicity, with research aimed at integrating pharmacogenomics into clinical practice for personalized cancer treatment. - Novel Drug Formulations and Delivery Systems:
Emerging research on novel drug formulations, including liposomal and nanoparticle-based delivery systems, highlights the trend toward improving drug solubility, bioavailability, and targeted delivery to tumor sites. - Real-World Evidence and Health Outcomes:
An increasing focus on real-world evidence and health outcomes related to chemotherapy and cancer treatment reflects a trend towards understanding treatment effectiveness in diverse patient populations beyond clinical trial settings. - Combination Regimens with Novel Agents:
The exploration of combination regimens that include novel agents, such as PARP inhibitors and immune checkpoint inhibitors, is on the rise, indicating a trend towards multi-modal treatment strategies.
Declining or Waning
- Traditional Chemotherapy Agents:
There appears to be a waning interest in studies solely focused on traditional chemotherapy agents without exploring novel combinations or mechanisms of action, as the field shifts towards more targeted and personalized approaches. - Non-Pharmacological Interventions:
Research focusing on non-pharmacological interventions in cancer treatment has decreased, with less emphasis on supportive care measures and lifestyle modifications that could complement pharmacological therapies. - Basic Science Studies:
There is a noticeable decline in the publication of basic science studies that do not directly relate to clinical applications or translational research, as the journal increasingly prioritizes clinically relevant findings.
Similar Journals
BRITISH JOURNAL OF PHARMACOLOGY
Advancing pharmacological science for a healthier tomorrow.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
MOLECULAR CANCER THERAPEUTICS
Advancing cancer therapy through molecular insights.MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.
Iranian Journal of Pharmaceutical Research
Elevating the discourse in pharmacology and pharmaceutics.Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.
ANTI-CANCER DRUGS
Unveiling Breakthroughs in Cancer TherapeuticsANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Unveiling Innovations in Drug Action and TherapeuticsNAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.
Journal of Pharmacological Sciences
Connecting researchers to drive pharmaceutical breakthroughs.Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.
International Journal of Cancer Management
Transforming cancer treatment strategies with impactful research.The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.
Pharmacogenomics & Personalized Medicine
Innovating patient care with tailored therapeutic approaches.Pharmacogenomics & Personalized Medicine is a premier open-access journal published by DOVE MEDICAL PRESS LTD, focusing on the vital intersection of pharmacogenomics, pharmacology, and personalized approaches to medicine. Launched in 2008 and based in New Zealand, this journal plays an essential role in disseminating cutting-edge research that aims to enhance therapeutic efficacy through individualized treatment strategies. With its Q3 ranking in both Molecular Medicine and Pharmacology as of 2023, Pharmacogenomics & Personalized Medicine is gaining momentum in the scientific community, providing a platform for researchers to explore significant findings and their implications for patient care. The journal's commitment to open access ensures that valuable information is readily available to a global audience, promoting collaboration and innovation across various fields of health science. We invite researchers, professionals, and students to contribute and explore groundbreaking studies that pave the way for advancements in personalized healthcare.
Advances in Pharmacological and Pharmaceutical Sciences
Elevating Pharmacological Knowledge for a Healthier Tomorrow.Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.
ACTA PHARMACOLOGICA SINICA
Championing High-Impact Research in PharmacologyACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.